Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Bone Metastases in Men With Hormone-Refractory Prostate Cancer|Bone Metastases in Subjects With Advanced Breast Cancer
Interventions: DRUG: Denosumab
Sponsor: Amgen